Welcome to our dedicated page for LakeShore Biopharma Co., Ltd. SEC filings (Ticker: LSBWF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LakeShore Biopharma Co., Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LakeShore Biopharma Co., Ltd.'s regulatory disclosures and financial reporting.
LakeShore Biopharma Co., Ltd. director and Chief Financial Officer Yu Rui reported initial beneficial ownership of a share option covering 203,464 underlying Ordinary Shares. The option has an exercise price of $1.225 per share and expires on December 13, 2034.
According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, subject to Yu Rui’s continued service to the company. The filing does not reflect any purchase or sale of shares, only this option holding.
LakeShore Biopharma Co., Ltd. director Pan Yue has filed an initial Form 3, which is the required first ownership report for company insiders. The filing identifies Pan Yue as a director but, in the provided data, does not show any reportable transactions or derivative positions.
LakeShore Biopharma Co., Ltd. director Shao Chunyang filed a Form 3, which is an initial statement of beneficial ownership for insiders. This filing reports no share purchases, sales, gifts, or other equity transactions and shows no derivative positions or holding entries for this reporting person.
LakeShore Biopharma Co., Ltd. filed an initial Form 3 to report the beneficial ownership status of director Zhao Jutao. The filing lists Zhao as a board member and indicates no reported transactions or holdings in either common stock or derivative securities at this time.
LakeShore Biopharma reported that its board’s special committee has received a revised, preliminary and non-binding proposal from Oceanpine Skyline Inc. and Oceanpine Merger Sub Inc. to acquire all outstanding ordinary shares they do not already own for US$0.06 per share in cash.
The bidders referenced arbitral awards totaling approximately RMB576.5 million against certain PRC subsidiaries, which they believe constitute a “Company Material Adverse Effect” under the existing November 2025 merger agreement and give them the right not to close on current terms. The special committee will evaluate the lower-priced offer, and the company stresses there is no assurance any definitive offer, agreement, or transaction will ultimately be completed.
LakeShore Biopharma’s controlling shareholder group filed Amendment No. 5 to its Schedule 13D, outlining a sharply revised going‑private proposal. The consortium now proposes to buy all publicly held ordinary shares at US$0.06 per share, compared with the prior US$0.90 offer, via equity funding and rollover of existing holdings.
The filing cites arbitral awards imposing approximately RMB576.5 million of monetary liabilities and related litigation uncertainty as key reasons for the lower price, warning these could materially weaken the company’s financial condition. If completed, the merger would take LakeShore private, terminate SEC registration and remove its shares from the OTC Pink market. The proposal remains non‑binding, with no assurance that definitive agreements or a transaction will be consummated.
LakeShore Biopharma Co., Ltd has called an extraordinary general meeting of shareholders for February 12, 2026 at 11 a.m. (Beijing time) in Beijing. Shareholders will be asked to consider and vote on authorizing and approving a previously announced Agreement and Plan of Merger with Oceanpine Skyline Inc. and its subsidiary Oceanpine Merger Sub Inc., along with a related Cayman Islands plan of merger.
At the effective time of the merger, Merger Sub will merge into LakeShore Biopharma, which will survive as a wholly owned subsidiary of Oceanpine Skyline Inc. If completed, the merger will result in LakeShore Biopharma becoming a privately held company, and its ordinary shares and warrants will no longer be quoted on any public marketplace, including the OTC Pink tier, and will cease to be registered under the U.S. securities laws.
The board of directors, following a unanimous recommendation from a special committee of independent directors, has approved the merger documents and resolved to recommend that shareholders vote FOR the proposals. Shareholders of record as of 5 p.m. Cayman Islands time on January 16, 2026 are entitled to attend and vote at the meeting. Additional details are provided in the Schedule 13E-3 transaction statement and definitive proxy statement filed with the SEC.